FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280640050> ?p ?o ?g. }

• W4280640050 endingPage "1043" @default.
• W4280640050 startingPage "1035" @default.
• W4280640050 abstract "Multi-agent induction chemotherapy (IC) improves response rates in younger patients with acute myeloid leukemia (AML); however, relapse remains the principal cause of treatment failure. Improved induction regimens are needed. A prospective single-center phase Ib/II study evaluating fludarabine, cytarabine, G-CSF, and idarubicin combined with venetoclax (FLAG-IDA + VEN) in patients with newly diagnosed (ND) or relapsed/refractory AML. The primary efficacy endpoint was assessment of overall activity (overall response rate [ORR]: complete remission [CR] + CR with partial hematologic recovery [CRh] + CR with incomplete hematologic recovery [CRi] + morphologic leukemia free state + partial response). Secondary objectives included additional assessments of efficacy, overall survival (OS), and event-free survival (EFS). Results of the expanded ND cohort with additional follow-up are reported. Forty-five patients (median age: 44 years [range 20-65]) enrolled. ORR was 98% (N = 44/45; 95% credible interval 89.9%-99.7%). Eighty-nine percent (N = 40/45) of patients attained a composite CR (CRc + CRh + CRi) including 93% (N = 37/40) who were measurable residual disease (MRD) negative. Twenty-seven (60%) patients transitioned to allogeneic stem cell transplant (alloHSCT). Common non-hematologic adverse events included febrile neutropenia (44%; N = 20), pneumonia (22%, N = 10), bacteremia (18%, N = 8), and skin/soft tissue infections (44%, N = 20). After a median follow-up of 20 months, median EFS and OS were not reached. Estimated 24-month EFS and OS were 64% and 76%, respectively. FLAG-IDA + VEN is an active regimen in ND-AML capable of producing high MRD-negative remission rates and enabling transition to alloHSCT when appropriate in most patients. Toxicities were as expected with IC and were manageable. Estimated 24-month survival appears favorable compared to historical IC benchmarks." @default.
• W4280640050 created "2022-05-22" @default.
• W4280640050 creator A5000750846 @default.
• W4280640050 creator A5016368595 @default.
• W4280640050 creator A5016607292 @default.
• W4280640050 creator A5020340537 @default.
• W4280640050 creator A5021380291 @default.
• W4280640050 creator A5027786056 @default.
• W4280640050 creator A5029750735 @default.
• W4280640050 creator A5035605515 @default.
• W4280640050 creator A5048163555 @default.
• W4280640050 creator A5049385583 @default.
• W4280640050 creator A5050041791 @default.
• W4280640050 creator A5051949215 @default.
• W4280640050 creator A5055045706 @default.
• W4280640050 creator A5056317446 @default.
• W4280640050 creator A5061026876 @default.
• W4280640050 creator A5067227071 @default.
• W4280640050 creator A5069176297 @default.
• W4280640050 creator A5070065917 @default.
• W4280640050 creator A5075581944 @default.
• W4280640050 creator A5079262854 @default.
• W4280640050 creator A5079433157 @default.
• W4280640050 creator A5080350639 @default.
• W4280640050 creator A5084379902 @default.
• W4280640050 creator A5088234044 @default.
• W4280640050 creator A5088307376 @default.
• W4280640050 creator A5089295627 @default.
• W4280640050 creator A5091492845 @default.
• W4280640050 date "2022-05-30" @default.
• W4280640050 modified "2023-10-15" @default.
• W4280640050 title "Venetoclax combined with <scp>FLAG‐IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia" @default.
• W4280640050 cites W2069448515 @default.
• W4280640050 cites W2118270328 @default.
• W4280640050 cites W2142830602 @default.
• W4280640050 cites W2148883973 @default.
• W4280640050 cites W2159507916 @default.
• W4280640050 cites W2318674152 @default.
• W4280640050 cites W2559537906 @default.
• W4280640050 cites W2715749014 @default.
• W4280640050 cites W2735569737 @default.
• W4280640050 cites W2760499085 @default.
• W4280640050 cites W2794480810 @default.
• W4280640050 cites W2802609999 @default.
• W4280640050 cites W2996657019 @default.
• W4280640050 cites W3000515035 @default.
• W4280640050 cites W3043154717 @default.
• W4280640050 cites W3048827006 @default.
• W4280640050 cites W3092079205 @default.
• W4280640050 cites W3096212403 @default.
• W4280640050 cites W3130903278 @default.
• W4280640050 cites W3146541588 @default.
• W4280640050 cites W3164043037 @default.
• W4280640050 cites W3170494628 @default.
• W4280640050 cites W3176370909 @default.
• W4280640050 cites W3183370518 @default.
• W4280640050 cites W4237543851 @default.
• W4280640050 cites W4376595466 @default.
• W4280640050 doi "https://doi.org/10.1002/ajh.26601" @default.
• W4280640050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35583199" @default.
• W4280640050 hasPublicationYear "2022" @default.
• W4280640050 type Work @default.
• W4280640050 citedByCount "24" @default.
• W4280640050 countsByYear W42806400502022 @default.
• W4280640050 countsByYear W42806400502023 @default.
• W4280640050 crossrefType "journal-article" @default.
• W4280640050 hasAuthorship W4280640050A5000750846 @default.
• W4280640050 hasAuthorship W4280640050A5016368595 @default.
• W4280640050 hasAuthorship W4280640050A5016607292 @default.
• W4280640050 hasAuthorship W4280640050A5020340537 @default.
• W4280640050 hasAuthorship W4280640050A5021380291 @default.
• W4280640050 hasAuthorship W4280640050A5027786056 @default.
• W4280640050 hasAuthorship W4280640050A5029750735 @default.
• W4280640050 hasAuthorship W4280640050A5035605515 @default.
• W4280640050 hasAuthorship W4280640050A5048163555 @default.
• W4280640050 hasAuthorship W4280640050A5049385583 @default.
• W4280640050 hasAuthorship W4280640050A5050041791 @default.
• W4280640050 hasAuthorship W4280640050A5051949215 @default.
• W4280640050 hasAuthorship W4280640050A5055045706 @default.
• W4280640050 hasAuthorship W4280640050A5056317446 @default.
• W4280640050 hasAuthorship W4280640050A5061026876 @default.
• W4280640050 hasAuthorship W4280640050A5067227071 @default.
• W4280640050 hasAuthorship W4280640050A5069176297 @default.
• W4280640050 hasAuthorship W4280640050A5070065917 @default.
• W4280640050 hasAuthorship W4280640050A5075581944 @default.
• W4280640050 hasAuthorship W4280640050A5079262854 @default.
• W4280640050 hasAuthorship W4280640050A5079433157 @default.
• W4280640050 hasAuthorship W4280640050A5080350639 @default.
• W4280640050 hasAuthorship W4280640050A5084379902 @default.
• W4280640050 hasAuthorship W4280640050A5088234044 @default.
• W4280640050 hasAuthorship W4280640050A5088307376 @default.
• W4280640050 hasAuthorship W4280640050A5089295627 @default.
• W4280640050 hasAuthorship W4280640050A5091492845 @default.
• W4280640050 hasConcept C126322002 @default.
• W4280640050 hasConcept C136119220 @default.
• W4280640050 hasConcept C141071460 @default.
• W4280640050 hasConcept C202444582 @default.
• W4280640050 hasConcept C2776611710 @default.

• next